-

Tenpoint Therapeutics to Participate in Upcoming Investor Conferences and Medical Meetings

LONDON & WARREN, N.J.--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced participation in upcoming investor conferences.

  • Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY), September 14. Management will host 1x1 meetings.
  • Citizens Private Ophthalmology Summit (Virtual), September 17. Henric Bjarke, CEO, will present in a fireside discussion at 3:00 p.m. ET on September 17, and management will host 1x1 meetings.

Additionally, Tenpoint Therapeutics will participate in two upcoming medical meetings.

  • Academy 2026 Anaheim presented by the American Academy of Optometry (Anaheim, CA), September 30 – October 3. Academy 2026 Anaheim offers an opportunity to explore the latest advancements in optometry with more than 150 industry-leading exhibitors, innovative papers and posters, and networking opportunities. Visit Tenpoint Therapeutics at Booth 965.
  • The American Academy of Ophthalmology Annual Meeting 2026 (New Orleans, FL), October 9 – 12. This conference brings leaders in the profession together with physicians from across the world for a premier educational experience. Visit Tenpoint Therapeutics at Booth 1955.

To request a meeting with the Tenpoint Therapeutics team, please contact the Morgan Stanley and Citizens conference representatives or contact the Company’s investor relations team at tenpoint@gilmartinir.com.

About Tenpoint Therapeutics

Tenpoint Therapeutics, Ltd. is a global commercial ophthalmic pharmaceutical company focused on the commercialization of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent eye drop for the treatment of presbyopia, a condition that affects nearly 128 million people in the U.S. and approximately 2 billion people globally.1,2 By understanding real-world needs and partnering with eye care professionals, Tenpoint is working to bring innovation to the aging eye.

To learn more, visit tenpointtherapeutics.com and connect on LinkedIn.

____________________

1 American Optometric Association Health Policy Institute. New Approaches to Presbyopia. 2023. Accessed November 5, 2025. Available at https://www.aoa.org/AOA/Documents/Advocacy/HPI/presbyopia%20brief%20HPI%20Final.pdf.

2 National Eye Institute. Presbyopia. National Eye Institute. December 4, 2024. https://www.nei.nih.gov/learn-about-eye-health/eyeconditions-and-diseases/presbyopia. Accessed January 7, 2026.

 

Contacts

Media:
Brandi Robinson
media@tenpointtx.com

Eye Care Trade Media:
Michele Gray
michele@mgraycommunications.com

Investors:
Ami Bavishi or Nick Colangelo
Gilmartin Group LLC
tenpoint@gilmartinir.com

Tenpoint Therapeutics, Ltd.


Release Versions

Contacts

Media:
Brandi Robinson
media@tenpointtx.com

Eye Care Trade Media:
Michele Gray
michele@mgraycommunications.com

Investors:
Ami Bavishi or Nick Colangelo
Gilmartin Group LLC
tenpoint@gilmartinir.com

More News From Tenpoint Therapeutics, Ltd.

Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults

LONDON & WARREN, N.J.--(BUSINESS WIRE)--Tenpoint Therapeutics announced the submission of an MAA to the United Kingdom’s MHRA for the review of YUVEZZI™ for the treatment of presbyopia....

Tenpoint Therapeutics Announces United Kingdom YUVEZZI™ Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults

LONDON & WARREN, N.J.--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced the submission of a Marketing Authorization Application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for the review and approval of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% – a once-daily, dual-ag...

Tenpoint Therapeutics Launches YUVEZZI™ Direct-to-Consumer Campaign Featuring a Cast of Hand-Crafted Puppets Giving a Voice to the Everyday Fusses of Blurry Close-Up Vision

LONDON & WARREN, N.J.--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced the launch of Friends of the Presbyopians, its first national consumer campaign for YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent, once-daily prescription eye drop approved by the U.S. Food and Drug Administration...
Back to Newsroom